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Introduction: Most adults with moderate to severe traumatic brain injury (TBI) report 
persistent sleep-wake disturbances. Whether these complaints are either associated with 
abnormal sleep-wake patterns or can be explained by TBI-related characteristics is unclear. 
The present study aimed at characterising the subjective and objective sleep-wake patterns in 
TBI adults by taking into consideration the influenc  of TBI severity, common comorbidities 
and psychoactive medication. 
Methods: Thirty-four adults with moderate-severe TBI (one to four years post-injury) were 
compared to 34 controls. Sleepiness, fatigue, sleep quality, mood, and pain were assessed 
with questionnaires. A seven day sleep diary and actigr phy were used to document sleep and 
wake patterns.  
Results: Compared to controls, TBI participants reported more sleepiness and fatigue, as well 
as poorer sleep quality. On actigraphy, they had earlier bedtime and longer time spent in bed, 
but equivalent sleep efficiency during the nighttime episode compared to controls. TBI 
participants also took more naps and accumulated more time asleep over the 24h period than 
controls. These group differences were accentuated when only TBI adults using psychoactive 
medication were included. More comorbidities, more severe injuries and longer hospital stay 
were positively correlated with fatigue, sleepiness and sleep duration.   
Conclusions: Our results showed that despite complaints regarding sleep and diurnal 
functioning, TBI survivors have very marginal changes in their objective sleep-wake 
schedules. Prolonged time spent in bed may reflect an attempt to increase their sleep duration 
in response to fatigue and sleepiness. TBI adults who use psychoactive medication are those 
with more evident changes in their sleep-wake schedules. 
















Sleep-wake disturbances (SWD) are reported by up to 70% of patients in the months 
following traumatic brain injury (TBI) [1-3]. An excessive need for sleep and the inability to 
maintain long periods of wakefulness during the daytime are an important part of the reported 
SWD [4,5]. As documented with sleep diaries and questionnaires [1,3,6], these difficulties 
may translate into earlier bedtimes, longer nighttime sleep duration, more daytime naps and a 
greater level of sleepiness and fatigue. These complaints are not specific to the early recov ry 
period following the TBI, as they last several years fter the injury in 20-30% of adults with 
TBI [6-8], leading to significant disabilities and impeding a return to normal life [6,9,10].  
Despite the high frequency of complaints of increased sleep need and difficulties 
sustaining consolidated periods of wakefulness following TBI, objective evidence of altered 
sleep and wakefulness patterns are relatively scarce. Studies using overnight 
polysomnography found both increased [11] or decreased [12] duration of nighttime sleep in 
the chronic stages of mild to severe TBI compared to controls. Although being the gold 
standard to assess sleep architecture, polysomnography does not provide an overview of 
sleep-wake behavior over the 24 h period. Three prospective and controlled studies have 
investigated sleep-wake patterns during the chronic phase of TBI (time post-TBI at testing > 1 
year) using actigraphy in adults with mild to severe TBI [8,11,13]. The first study found that 
patients who report a chronic increase in their sleep duration post-TBI have 2 h more sleep 
per 24 h cycle compared to controls, for up to four years following the TBI [8]. This same 
study also found a higher percentage of TBI patients wi h excessive daytime sleepiness as 
measured with multiple sleep latency tests, and more daytime naps as documented with 
actigraphy, when compared to controls[8]. The second study observed a longer total sleep time 
(1 h more per 24 h on average) compared to controls, in a sample of adults with mild to severe 















disorders [11]. Conversely, increased sleep duration over the 24 h period was not present 
among another sample of mild to severe TBI patients tested in average at three years post-
TBI, despite the fact that they had significant self-r ported sleepiness, fatigue or sleep 
complaints on questionnaires [13]. Actigraphy results in this study may have been influenced 
by the particularly high variability in terms of time since TBI ranging from four months to 13 
years.  
Among possible contributing factors, characteristics related to the TBI itself (eg, TBI 
severity and the presence of intracranial haemorrhage) or to its consequences, and 
comorbidities (eg, pain, depression and anxiety) have ll been associated with objective 
increases in total sleep time [7,8,14,15]. Yet, in previous prospective studies using actigraphy, 
all TBI severities (mild to severe) were included in the studied samples [8,11,13] and among 
TBI comorbidities, only symptoms of depression were evaluated by one study [13]. 
Furthermore, post-TBI symptoms necessitate long-term pharmacological management in 38-
77% of patients, particularly in individuals with moderate to severe TBI [1,16,17]. Yet, the 
use of psychoactive medication is rarely accounted for in TBI research on sleep [6,7,18-20]. 
Among previous prospective studies using actigraphy, medication status at the time of testing 
was not reported [11] or partially reported (only stimulant use was specified) [8] or limited 
(exclusion of patients using sleep medication, but inclusion of those using other psychoactive 
medications) [13], and the potential impact of medication use on SWD measures was not 
controlled. Patients taking psychoactive medications may represent those with a more 
complex recovery and be at higher risk of presenting SWD; their exclusion may therefore lead 
to an unrepresentative sample of TBI participants. In addition to physiological factors, 
psychosocial characteristics may also contribute to SWD. TBI patients, who are often young 
and unemployed, may sleep more than non-TBI individuals just because they have fewer 















considered in previous TBI studies using actigraphy during the chronic stage of TBI 
[8,11,13].  
The present study aimed (1) to evaluate sleep, daytime sleepiness and fatigue complaints 
in adults in the chronic stage of moderate to severe TBI; (2) to determine how these 
complaints are associated with sleep-wake patterns over the 24h period, measured with 
actigraphy; (3) to examine the association of subjectiv  and actigraphic sleep-wake measures 
with potential contributing factors, such as injury severity and TBI-related symptoms (ie, 
depression, anxiety and chronic pain), as well as the presence of obligations curtailing 
morning sleep; and (4) to explore whether SWD are more severe in TBI patients using 
psychoactive medication. We hypothesised that TBI patients with persistent comorbidities 
requiring the use of psychoactive medication would have greater injury severity than non-
medicated TBI survivors, report greater level of sleepiness/fatigue, and show longer sleep 
duration compared to both non-medicated TBI and controls groups. 
2 Materials and methods  
2.1 Participants  
In this cross-sectional study, we reviewed charts of all patients admitted to our tertiary 
trauma center hospital with a diagnosis of moderate to severe TBI from 2010 to 2015. TBI 
severity was confirmed by a neurosurgeon using standard criteria [21]. Briefly, TBI was 
defined as an alteration in brain function or other evidence of brain pathology caused by an 
external force. Moderate TBI was diagnosed in the case of an initial Glasgow Coma Scale 
(GCS) between 9 and 12, a loss of consciousness of 30 min to 24 h, and a post-traumatic 
amnesia of 1 to 14 days. Severe TBI was diagnosed when the initial GCS was between 3 and 
8, a loss of consciousness of more than 24 h was observed, and a post-traumatic amnesia 
persisted for several days or weeks. Inclusion criteria were: (1) being between 18 and 60 years 















four years. Based on the medical chart review, patients were excluded if they presented with: 
(1) diagnosed psychiatric, neurological or sleep disorders prior to or after the TBI; (2) a 
history of multiple TBI; or (3) chronic substance abuse. 
Based on our inclusion and exclusion criteria, 120 patients were contacted by phone (see 
Figure 1). Based on the telephone interview, participants were excluded if they presented: (1) 
daily use of hypnotic medication; (2) a self-reported body mass index > 40; 3) pregnancy; 4) 
jet lag due to trans-meridian travel in the month preceding the study or night work or shift 
work, leading to an atypical sleep schedule; or 5) inability to communicate in French or 
English. Inability to reach participants and eligiblity assessment performed in the phone 
interview excluded 70 subjects. Among the 50 remaining subjects, 40 agreed to participate in 
our study. Thirteen of these patients were using psychoactive medication (see Table 4) at the 
time of the study.  
For comparison, a group of 38 healthy controls having a similar age range and sex 
distribution that TBI group was recruited through local advertisements and newspaper ads. 
We excluded subjects with a self-history of diagnosed TBI (for the control group only), 
psychiatric, neurologic or sleep disorders. The same criteria were used for TBI subjects; 
although, in TBI subjects, we also had access to their medical records (allowing confirmation 
of self-reported medical history). Control and TBI subjects with clinically significant scores 
on questionnaires were not excluded, as we wanted to apply the same criteria in both groups. 
This study was approved by the Research Ethics Board f the institution and written informed 
consent was obtained from each participant. 
2.2 Overview of the protocol 
Recruitment of participants and data collection were performed by the research team. 
Participants were first asked to wear a wrist actigraphy and to fill out a sleep diary for seven 















night polysomnographic recording to assess sleep disor ers. We then conducted a structured 
interview and a series of questionnaires to assess subjective SWD, TBI outcome, and current 
symptomatology.  
2.3 Subjective measures of sleep-wake disturbances 
The Epworth Sleepiness Scale (ESS) [22], the Fatigue Severity Scale (FSS) [23] and the 
Pittsburgh Sleep Quality Index (PSQI) [24], were used to assess symptoms of daytime 
sleepiness, fatigue, and sleep quality, respectively. Higher scores on any of these scales or 
index indicate higher levels of symptomatology. 
A seven day sleep diary provided information on the sleep schedules (bedtime and rise 
time) for nighttime sleep and daytime naps, on daily medications, and on the presence of 
personal obligations in the morning (eg, childcare, work, school, medical appointments). 
2.4 Objective measures of sleep-wake disturbances 
Participants wore an actigraph device (Actiwatch Spectrum or Actiwatch-L, Philips-
Respironics, Andover, MA) on their non-dominant wrist for seven consecutive days to 
measure their sleep-wake patterns. The actigraph measur s physical motion in all direction in 
1-min epochs. The device concurrently records light exposure. Participants were instructed to 
press a button on the actigraph to indicate when thy laid down at any time during the day for 
sleep, and when they rose from bed. For each day of recording, we manually determined 
intervals of sleep first using the sleep diary, butwhen sleep information was deemed invalid 
(eg, the participant forgot to enter information), sleep episodes were determined according to 
button presses, level of motor activity and changes in light intensity [25].  
For each identified nighttime and daytime sleep episode, each minute of activity data was 
scored as “wake” or “sleep” by the dedicated software (Actiware, version 6.0.8, Philips-
Respironics), using a medium wake threshold (40 activity counts). We used the “wake 















to detect wakefulness) and accuracy to measure the rest-activity cycle, as showed among 
healthy individuals and clinical TBI population [26, 7]. The duration of an identified sleep 
episode corresponds to the total time spent in bed,an  total sleep time corresponds to the 
number of minutes scored “sleep” during the sleep episode. For the main nocturnal sleep 
episode, sleep efficiency ([percentage of time asleep] / [duration of time spent in bed]) was 
also computed as an objective estimate of sleep quality. For naps, time spent in bed and total 
sleep time was also computed, and the percentage of days with naps was calculated manually.  
2.5 TBI severity and outcomes 
TBI severity was assessed with data from the medical ch rts (ie, GSC upon admission, 
duration of post-traumatic amnesia, duration of hospital stay). To assess overall trauma 
severity of patients with multiple injuries, we computed the Injury Severity Score (ISS) [28], 
an established medical scale that scores each injury in different body regions (head, face, 
chest, abdomen, extremities, and external). The Glasgow Outcome Scale Extended (GOSE) 
[29] administered during the structured interview was used to evaluate functional outcome (3 
= lower severe disabilities, 4 = upper severe disabilities, 5 = lower moderate disabilities, 6 = 
upper moderate disabilities, 7 = lower good recovery, 8 = upper good recovery). The Beck 
Anxiety Inventory (BAI) [30] and the Beck Depression Inventory-second revision (BDI-II) 
[31] were used to assess symptoms of anxiety and depression, respectively. These 
questionnaires have also been previously validated in individuals with moderate to severe TBI 
[32,33]. Finally, the mean pain intensity experiencd over the last week was measured using a 
pain Numeric Scale (NS) ranging from 0 (no pain) to 10 (worst pain ever felt).  
2.6 Statistical analyses  
To investigate subjective and objective SWD during chronic TBI, we assessed group 
differences between TBI participants and controls using Student t-tests when normality 















appropriate for quantitative data. Chi-square (χ2) tests were used to assed group differences 
for nominal data. Pearson correlations were performed in the TBI group to test the association 
between subjective and objective estimates of sleep. We also used Pearson correlations to 
assess the association of subjective and objective sleep-wake measures with clinical variables 
of injury severity and chronic comorbidities after TBI. 
To test whether the use of psychoactive medication was associated with daytime 
sleepiness, fatigue, time spent in bed and total sleep time, TBI participants were divided into 
medicated and non-medicated groups. We assessed group differences between medicated TBI 
participants, non-medicated TBI participants and controls using analyses of variance 
(ANOVA) for quantitative data, and χ2 tests for nominal data. To determine between-group 
differences in the case of significant ANOVA, Tukey HSD post-hoc comparisons tests were 
used. Analyses were performed using SPSS (SPSS Inc., Chicago, IL) and statistical 
significance was set at p < 0.05.  
3 Results  
3.1 Patient characteristics 
Six TBI participants and four controls were excluded from the initial sample due to 
artefacts in actigraphic recordings or failure to consistently wear the actigraph, leaving 34 
participants in each group for analyses. Table 1 show  participants’ characteristics and 
statistics. TBI and control groups were comparable on age, sex, and marital status. However, 
compared to healthy controls, TBI participants had less years of education. TBI participants 
were tested on average 23.2 ± 9.9 months following the injury. Most TBI participants had 
recovered sufficiently to carry out activities of daily living without supervision (eg, toileting 
and self-care, preparing food, driving), and to reint grate social activities as reflected by 
GOSE scores (range 4 - 8). However, 55.9% of TBI participants were on sick leave or 















Clinically significant symptoms of anxiety (Beck Anxiety Inventory above 9) was reported by 
52% (18/34) of TBI patients vs. 11% (4/34) of contrls, and significant symptoms of 
depression (Beck Depression Inventory above 13) was reported by 67% (23/34) of TBI 
participants versus 2% (1/34) of controls. Self-reported pain level was also greater in TBI 
group compared to controls. Two of the medicated participants (ID 9 and 11 in Table 4 and 
Figure 2) had an apnea-hypopnea index of 20.8/h and 17.2/h. Sleep diary was missing or 
incomplete for 14.7% of the controls and 23.5% of the TBI participants. 
 
3.2 Group differences on subjective measures of sleep-wake disturbances  
Results and statistics for sleep-wake questionnaires a  presented in Table 2. The TBI 
group reported greater levels of daytime sleepiness and fatigue than controls. As shown by 
higher scores on the PSQI, global quality of sleep was significantly poorer in TBI participants 
compared to controls. More specifically, scores on sub-components of the index indicate that 
the TBI group complained of delayed sleep onset and lower sleep quality, and experienced 
sleep disturbances and daytime dysfunction more frequently than controls. 
3.3 Group differences on objective measures of sleep-wake disturbances  
Results and statistics for actigraphy are presented in Table 3. The percentage of days 
without morning obligations was almost identical in the two groups: 56.9 ± 32.3% in TBI 
patients compared to 54.4 ± 33.2% in controls (t53 = 2.81; 95% CI = -15.3 − 20.2; p = 0.7). 
Therefore, all analyses were performed by combining days with and without occupational 
obligations.  
We found that TBI participants had earlier bedtime, longer time spent in bed during the 
nighttime episode and more frequent daytime naps. Compared to controls, TBI patients also 
spent more time in bed and accumulated more time asle p when all sleep episodes over the 24 















3.4 Associations between subjective and objective sleep-wake measures in the TBI 
group 
We then investigated whether sleep, fatigue and sleepin ss complaints measured with 
questionnaires were associated with objective sleep-wake patterns measured with actigraphy 
in the TBI group. The percentage of days with naps wa associated with the ESS and the FSS, 
such that a greater percentage of days with naps was associated with higher levels of 
sleepiness (r = 0.36, p = 0.03) and fatigue (r = 0.31, p = 0.03). We also found that TBI 
participants who spent more time asleep per 24 h tended to report more fatigue (r = 0.31, p = 
0.06), as per the FSS. No other significant associati ns were found between subjective and 
objective sleep-wake measures. 
3.5 Associations between sleep-wake measures and severity of traumatic injuries  
Correlations were performed between sleep-wake measur s and TBI characteristics in 
order to identify clinical variables that could be associated with higher risk of SWD. Two 
clinical variables measured in the acute stage of injury were associated with SWD in the 
chronic stage: the Injury Severity Score and the hospital stay duration. Higher Injury Severity 
Scores were associated with more fatigue (r = 0.44; p = 0.009), more sleepiness (r = 0.34, p = 
0.04), a higher proportion of days with a nap (r = 0.38, p = 0.02) and more total sleep time per 
24 h (r = 0.41, p = 0.01). Similarly, longer hospital stay duration was associated with more 
fatigue (r = 0.59; p = 0.007) and higher proportion of days with a nap (r = 0.48, p = 0.004).  
3.6 Associations between sleep-wake measures and comorbidities in the TBI group 
Overall, subjective measures of fatigue were significantly correlated with psychological 
symptoms (eg, anxiety and depression), while pain was associated with a poorer subjective 
sleep quality. Significant correlations were found between fatigue and mood questionnaires, 
such that increased levels of fatigue were associated with more severe symptoms of anxiety (r 















between PSQI (global score) and pain intensity (r = 0.67; p = 0.00001), such that TBI patients 
with greater pain complained of worse sleep quality.  
No associations were found between objective measurs of sleep and wakefulness 
measured with actigraphy (ie, nocturnal, daytime and the 24 h period sleep analyses) and 
comorbidity variables measured with questionnaires (ie, anxiety, depression, and pain). 
3.7 Sleep-wake disturbances in medicated versus non-medicated TBI participants 
Of the 34 TBI participants, 13 were using psychoactive medication on a regular basis at 
time of testing. All started their treatment after occurrence of the TBI. Details of drug 
categories for each participant are presented in Table 4.  
More TBI participants who used medication were unemployed (11/13) compared to non-
medicated TBI participants (8/21), but they did notdiffer significantly from TBI participants 
without medication and from controls for the percentage of days without morning obligations 
(71.9 ± 29.4% in medicated TBI, 49.0 ± 32.5% in non-medicated TBI, and 54.4 ± 33.2% in 
controls, F2,52 = 1.52; p = 0.22). Compared to TBI participants without medication, TBI 
participants with medication had a longer hospital s y in the acute stage (t30= 2.74; 95% CI = 
3.9 – 29.3; p = 0.01), a higher Injury Severity Score (t32 = 2.21; 95% CI = 0.6 – 13.6; p = 
0.03) and lower GOSE scores (t30= -2.56; 95% CI = -1.9 − -0.2; p = 0.01). Regarding co-
morbidities, there was no significant difference between medicated and non-medicated TBI 
participants for the measures of depression, anxiety or pain level.  
Table 5 presents the comparisons between medicated TBI participants, non-medicated 
TBI participants and controls for subjective and objective measures of SWD. For subjective 
measures, reported fatigue level was higher in medicated TBI participants compared to non-
medicated TBI participants (post-hoc test, p = 0.03) and compared to controls (post-hoc test, p 
= 0.00007). However, reported level of fatigue in TBI participants without medication did not 















For objective measures, total sleep time during nighttime period was higher in medicated 
TBI participants when compared to both non-medicated TBI participants (post-hoc test, p = 
0.02) and controls (post-hoc test, p = 0.04). Similarly, a significant group effect was found for 
total time asleep per 24 h and total time spent in bed per 24 h; post-hoc analyses showed that 
medicated TBI participants had longer total sleep time and time spent in bed per 24 h than 
both the non-medicated TBI participants (p = 0.01 and p = 0.03 respectively) and controls (p 
= 0.002 and p = 0.001 respectively) (Figure 2a and 2b respectively). We also observed a 
group effect on the percentage of days with naps, which showed that medicated TBI 
participants tended to take more naps than controls (p = 0.05). Again, TBI participants 
without medication did not differ from controls. 
4 Discussion 
The first objective of our study was to evaluate SWD using subjective and objective 
measures in adults during the chronic phase of a moderate to severe TBI. Our results 
confirmed previous findings that showed more complaints of fatigue, sleepiness, and poorer 
sleep quality in the TBI population compared to non-TBI adults [1-3,34]. Despite a 
significantly lower subjective sleep quality, TBI participants had a total sleep time and sleep-
efficiency during nighttime nearly identical to tha of control participants, which is in line 
with Sinclair et al., findings [13].  These results are in contradiction with those reported in 
two previous studies where they found increased total sleep time, but no significant 
complaints of fatigue and sleepiness in TBI subjects compared to controls [8,11]. Differences 
between studies regarding subjective fatigue/sleepiness complaints and objective sleep 
measures could be due to the heterogeneity of the TBI population in terms of injury severity, 
recovery, psychoactive medication used and comorbidities. Although it is noteworthy that our 
group subjects were comparable to those included in previous studies in terms of self-reported 















The most striking difference between TBI participants and controls in our study was that 
TBI participants spent more time in bed over a 24 h period, due to an earlier bedtime and a 
higher frequency of daytime naps. The significant association between frequency of naps and 
scores of fatigue and sleepiness suggests that our TBI survivors attempted to relieve fatigue 
and sleepiness by increasing their sleep time. This strategy was partially successful for 
increasing time asleep: by spending an additional 45 min in bed, TBI participants were able to 
sleep on average 28 min more that controls on the 24 h period. However, reporting daytime 
impairment, spending more time in bed and adopting a  early bedtime may delay sleep onset 
at night, which are all consistent with insomnia symptoms [35]. The longer sleep latency 
reported by TBI participants on questionnaires, coupled with a lack of feeling refreshed after 
sleeping, may explain their dissatisfaction with sleep quality. Our findings suggest that 
monitoring time spend in bed over the 24 h period culd be of clinical interest to quantify 
sleep effort and insomnia-related symptoms following TBI. However time spent in bed on the 
24 h period was not reported in previous prospectiv studies using actigraphy [8,11,13].  
If daytime fatigue and sleepiness are not related to sleep patterns, they could result from 
perturbations in wake regulation. Potential pathophysiological mechanisms include a 
reduction in the secretion of the wake-promoting neurotransmitter hypocretin, which may 
increase sleepiness and total sleep time during the acute stage of TBI, and contribute to 
maintaining this sleep-wake pattern during the chronic stage of TBI [15,36]. Furthermore, the 
study of post-mortem brain tissue of TBI patients has revealed an important loss of wake-
maintaining histamine neurons located in the posterior hypothalamus [37,38]. Therefore, 
higher daytime sleepiness may reflect a physiological difficulty maintaining wakefulness 
rather than an increased need for sleep.  
The second objective of this study was to investigate whether comorbidities and injury 















complaints of fatigue, sleepiness and low sleep quality re strongly associated with a high 
degree of distress (anxiety, depression, pain), which is in line with previous studies [1,2,39]. 
Conversely, the level of distress was not associated with actigraphic measures of sleep. We 
cannot, however, rule out the possibility that mood disturbances or pain were associated with 
more subtle measures of sleep fragmentation, as previously observed in TBI studies using 
polysomnography [18,19]. It is well established that SWD have a strong two-way relationship 
with mood disorders [40,41] and with medical conditions producing pain [42-44], each 
worsening the symptoms of the other. Therefore, interventions aiming at improving sleep 
hygiene (eg, spending less time in bed when not sleeping), and acquisition of better coping 
strategies to reduce fatigue and sleepiness could not only improve sleep, vigilance and energy 
levels, but also mood and pain symptoms in the TBI population. Cognitive-behavioral therapy 
[45,46], melatonin administration [47] and blue light therapy [48] all showed promising 
results in improving subjective sleep quality and re ucing fatigue and sleepiness. 
Factors other than common TBI comorbidities may also explain SWD. In the present 
study, both the overall severity score of injuries and longer hospital stays were associated 
with increased subjective fatigue and sleepiness, as well as with more napping and increased 
total time asleep per 24 h. However, correlation analyses failed to demonstrate significant 
associations between the severity of the TBI itself (duration of PTA, GCS score) and sleep-
wake complaints or measures. This finding is in agreement with previous studies, in which no 
relationship was found between TBI severity and sleep duration more than one-year post-TBI 
[8,11,13]. The exploratory analyses of SWD in the 13 TBI participants who were taking 
psychoactive medications showed that this sub-group sustained greater overall injury severity, 
and accounted for the majority of differences betwen TBI adults and controls for fatigue, 
sleepiness, total sleep time and time spent in bed.Indeed, participants taking psychoactive 















increased time asleep was not observed in TBI participants who were not taking psychoactive 
medication. Moreover, despite that medicated TBI participants tended to have fewer morning 
obligations than controls, the same results were found when only days without obligations 
were analysed (data not shown). When comparing our results with those reported in previous 
studies, we found interesting similarities. For example, medicated TBI subjects had a total 
time asleep of 8.0 ± 0.8 h per 24 h, while previous st dies reported 8.1 ± 0.5 h in TBI subjects 
(whose medication status at time of testing was not reported) [7,11]. However, in the present 
study, total sleep time for TBI participants who did not use psychoactive medication was 
similar to what was observed in controls of our study and one previous study (Imbach et al., 
[11]: 7.1 ± 0.7 h vs. our study: 7.0 ± 0.8 h). In the study by Sinclair et al., (where 
psychoactive medication was taken by a part of their TBI participants), no significant increase 
in total sleep time per 24 h was found in their TBI participants compared to their controls 
[13].  
Based on our findings, it is plausible that studies using more strict exclusion criteria (ie, 
excluding TBI participants taking psychoactive medications) may fail to observe an increased 
sleep duration following TBI, while those using more liberal criteria would be more likely to 
observe this sleep pattern. Our study raises questions regarding the inclusion of those 
participants in studies investigating the consequences of TBI, as these persons represent a 
significant proportion of all moderate to severe TBI, but may differ from non-medicated TBI 
adults in terms of functional outcome. Studies excluding TBI survivors taking medications 
can miss out on an important reality experienced by TBI adults and observed by clinicians. 
Yet, mixing participants using and not using medications can blur the interpretation of results. 
We therefore suggest that future studies clearly describe medications taken by participants 















The present study had certain limitations. Although our findings indicated normal sleep 
duration and sleep efficiency among TBI participants, we cannot exclude the possibility of 
more subtle nighttime sleep disturbances. Indeed, crtain characteristics associated with the 
recuperative aspects of sleep (eg, slow waves, microarousals, percentage of specific sleep 
stages, etc.) can only be assessed using polysomnography. We also cannot exclude the 
possibility that the medication itself may have negative impacts on the sleep quality and, 
consequently, affect daytime fatigue and vigilance. In addition, while we agree that it is 
essential to control the possible effects of psychoa tive medication on outcome measures, the 
small sample of medicated patients (n=13) allowed us to establish only preliminary 
associations between pharmacological treatment and change in sleep pattern following TBI. 
Exclusion of patients with daily use of hypnotics may have reduced the differences observed 
between TBI participants and controls on sleep-wake measures. Moreover, having excluded 
patients with comorbidities (eg, diagnosed mood disor ers, substance abuse) may reduce the 
generalizability of our results. Finally, missing data may not be at random, and may have 
impacted our statistics. 
5 Conclusion 
No objective trace of SWD could be found in our sample of moderate to severe TBI 
adults, despite the fact that they report high levels of daytime sleepiness and fatigue as well as 
low sleep quality. Nevertheless, our results show that individuals with TBI spend more time 
in bed and sleep slightly more, most probably in an effort to decrease daytime sleepiness and 
fatigue. It is important to highlight that daytime complaints and increased sleep duration were 
mainly found in TBI survivors using psychoactive medications. Therefore, our results 
demonstrate that taking into account the use of psychoactive medications during both 
recruitment and data analysis may be of prime importance in future studies that aim to 
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Figure legends 
Figure 1. Flow chart presenting patient recruitment and inclusion in the study 
Figure 2. Total sleep time (A) and time spent in bed (B) on the 24 h period for TBI 
participants and controls (med+: with medication, med-: without medication). Medicated TBI 
are identified by their number ID (cf. Table 4). No group difference was found between TBI 
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χ2 or t 
value 
95% CI  p value 
Demographic variables      
Male, n (%) 23 (67.6) 23 (67.6) 0.00  1.00 
Age at testing, years 30.6 ±12.3 31.2 ±13.0 -0.21 -6.8 − 5.5 .83 
Education, years 12.3 ±2.4 15.0 ±2.5 -4.38 -3.9 − -1.5 .00004 
Marital status       
Single, n (%) 18 (52.9) 21 (61.8) 0.54  .46 
Married/civil union, n (%) 16 (47.1) 13 (38.2)    
In charge of children, n (%) 3 (8.8) 5 (14.7) 0.56  .45 
Occupation at testing       
Sick leave or unemployed, n (%)  19 (55.9) 9 (27.3) 5.70  .05 
Full time employed/student, n (%)  10 (29.4) 15 (45.5)    
Part time employed/student, n (%)  5 (14.7) 9 (27.3)    
Comorbidities      
Beck Anxiety Inventory 10.9 ± 8.6 3.5 ± 4.4 4.42 4.0 −10.7 6.2E-8 
Beck Depression Inventory 16.4 ± 10.3 3.8 ± 4.5 6.46 8.7 − 16.5 .00005 
Average pain (NS) a 2.8 ± 2.1 1.0 ± 1.6 3.89 0.9 − 2.7 .007 
Clinical variables of TBI      
Delay post-injury, months 23.2 ± 9.9 -    
GCS upon admission 8.7 ± 3.2 -    
Post traumatic amnesia, days b 12.1 ± 14.1 -    
Duration of hospital stay, days 27.8 ± 17.2 -    
Injury Severity Score 25.7 ± 9.6  -    
GOSE score c 5.9 ± 1.3 -    
Data are expressed as means ±SD or frequency (n) and percentage (%). CI = confidence interval 
of the difference. NS = numeric scale; GCS = Glasgow Coma Scale; GOSE = Glasgow Outcome 
Scale Extended. Higher scores on questionnaires indicate higher levels of symptomatology.  
a Average pain was missing for 5.8% of the TBI participants.  
b Duration of post-traumatic amnesia was missing for 2.9% of the TBI participants.  
c GOSE score was missing for 5.8% of the TBI participants. 




















t value 95% CI  p value 
Epworth Sleepiness Scale 9.5 ± 4.9 6.7 ± 4.2 2.56 0.6 – 5.1 .01 
Fatigue Severity Scale 41.3 ± 14.9 29.3 ± 11.9 3.65 5.4 − 18.6 .001 
Pittsburgh Sleep Quality Index a – global score 6.4 ± 3.2 4.2 ± 2.1 3.22 0.8 − 3.5 .002 
Sub-components scores   U value   
Sleep quality 1.2 ± 0.7 0.8 ± 0.6 688.0  .03 
Sleep latency 1.4 ± 1.1 0.6 ± 0.5 781.0  .001 
Sleep duration 0.5 ± 0.8 0.3 ± 0.4 609.0  .32 
Sleep efficiency 0.5 ± 0.9 0.2 ± 0.4 615.0  .23 
Sleep disturbances 1.2 ± 0.5 1.0 ± 0.3 654.0  .05 
Use of sleep medication 0.3 ± 0.7 0.1 ± 0.4 585.5  .42 
Daytime dysfunction 1.1 ± 0.7 0.7 ± 0.7 681.5  .05 
Data are expressed as means ±SD. CI = confidence interval of the difference. U value of Mann-
Whitney tests. Higher scores on questionnaires indicate higher levels of symptomatology. 
a Pittsburgh Sleep Quality Index was missing for 2.9% of the TBI participants.  














Table 3. Actigraphic measures of TBI and controls participants 
 
Variables 




t value 95% CI p value 
Nocturnal sleep      
Bedtime, h:min 23:52 ± 01:16 00:33 ± 01:20 -2.16 -01:18 − -00:03 .03 
Rise time, h:min 08:20 ± 01:25 08:29 ± 01:20 -0.45 -00:49 – 00:30 .64 
Time spent in bed, min 507.5 ± 71.06 474.3 ± 58.9 2.09 1.6 – 64.8 .04 
Total sleep time, min 434.6 ± 53.8 415.7 ± 56.6 1.40 -7.9 – 45.6 .16 
Sleep efficiency, % 86.0 ± 5.1 87.5 ± 4.0 -1.38 -3.8 −0.7 .17 
Daytime sleep (naps)      
Days with naps, % of all days recorded  29.9 ± 28.9 15.5 ± 20.6 2.36 2.2 – 26.6 .02 
Time spent in bed, min 70.5 ± 47.8 55.1 ± 38.8 1.11 -12.7 – 43.5 .27 
Total sleep time, min 62.1 ± 47.9 48.4 ± 34.3 1.01 -13.4 – 40.7 .31 
Analysis on the 24 h period      
Time spent in bed, min 525.7 ± 71.6 481.3 ± 56.8 2.82 13.01 – 75.6 .006 
Total sleep time, min 450.4 ± 55.9 422.08 ± 53.4 2.14 1.9 – 54.9 .03 














Table 4. Prescribed medications of TBI participants 
 
ID Medications Categories Doses (mg) nb/days 
1 Methyphenidate (Ritalin®) Psychostimulant 20 2 
Escitalopram (Cipralex®) Antidepressant 20 2 
Quetiapine (Seroquel®) Antipsychotic 25 1 
Ibuprofen (Advil®)  NSAID 200 3 
2 Methyphenidate (Concerta®) Psychostimulant 36 2 
Venlafaxine (Effexor®)  Antidepressant 37.5 1 
Trazodone (Apo-Trazodone®) Antidepressant 50 2 
3 Methyphenidate (Concerta®) Psychostimulant 27 1 
Methyphenidate (Concerta®) Psychostimulant 18 1 
4 Methyphenidate (Biphentin®) Psychostimulant 30 1 
Sertraline (Zoloft®) Antidepressant 50 1 
Gabapentin (Neurontin®) Anticonvulsant 800 1 
5 Methyphenidate (Concerta®) Psychostimulant 54 1 
6 Methyphenidate (Concerta®) Psychostimulant 54 1 
Methyphenidate (Concerta®) Psychostimulant 18 1 
Tadalafil (Cialis®) Other - - 
7 Lisdexamfetamine (Vyvanse®) Psychostimulant 60 1 
8 Venlafaxine (Effexor®) Antidepressant 37.5 1 
9 Citalopram (Celexa®) Antidepressant 20 1 
Pantoprazole (Protonix®) Other 40 1 
10 Venlafaxine (Effexor®) Antidepressant 75 1 
11 Escitalopram (Cipralex®)  Antidepressant 10 1  
Divalproex (Depakote® Epival®) Anticonvulsant 250 4  
Pregabalin (Lyrica®) Anticonvulsant 50 2  
Hydromorphone (Dilaudid®) Opioid  2 2 to 4  
Fluticazone (Advair HFA®) Other -  - 
Albuterol inhalation (Ventolin HFA®)  Other -  - 
12 Amitriptyline (Elavil®) Antidepressant 15 1 
Ibuprofen (Advil®) NSAID 200 4 to 5 
13 Divalproex (Depakote® Epival®) Anticonvulsant 500 2 
 














Table 5. Sleep-wake measures for medicated and non-medicated TBI participants and controls  
 
Variables 
Medicated TBI  
“A”  ( n= 13) 
Non-medicated TBI 
“B”  ( n= 21) 
Controls 
“C”  (n= 34) 
F value p value Post hoc analyses 
Questionnaires       
Epworth Sleepiness Scale 11.0 ± 5.4 8.7 ± 4.4 6.7 ± 4.2 4.34 .01 A>C, A=B, B=C 
Fatigue Severity Scale 48.5 ± 11.9 36.8 ± 15.1 29.3 ± 11.9 10.48 1.1E-7 A>B=C 
Pittsburgh Sleep Quality Index – global score 5.9 ± 2.5 6.8 ± 3.7 4.2 ± 2.1 5.56 .006 A=B, A=C, B>C 
Actigraphy       
Nocturnal sleep       
Bedtime, h:min 23:41 ± 01:16 23:58 ± 01:17 00:33 ± 01:20 2.50 .08  
Rise time, h:min 08:40 ± 01:21 08:07 ± 01:27 08:29 ± 01:20 0.74 .48  
Time spent in bed, min 538.8 ± 64.4 488.1 ± 69.3 474.3 ± 58.9 4.91 .01 A>C, A=B, B=C 
Total sleep time, min 463.1 ± 53.8 416.9 ± 46.8 415.7 ± 56.6 4.09 .02 A>B=C 
Sleep efficiency, % 86.0 ± 4.6 85.9 ± 5.5 87.5 ± 4.0 0.94 .39  
Daytime sleep (naps)       
Days with naps, % of all days recorded  34.7 ± 32.8 26.9 ± 26.6 15.5 ± 20.6 3.16 .04  A>C, A=B, B=C 
Time spent in bed, min 83.3 ± 73.6 62.3 ± 18.8 55.1 ± 38.8 1.23 .30  
Total sleep time, min 73.5 ± 74.4 54.7 ± 18.3 48.4 ± 34.3 1.05 .36  
Analysis on the 24 h period       
Time spent in bed, min 560.4 ± 60.6 504.2 ± 70.7 481.3 ±56.8 7.62 .001 A>B=C 
Total sleep time, min 482.6 ±50.7 430.5 ±50.2 422.08 ±53.4 6.57 .003 A>B=C 








































Title: Towards a better understanding of increased sleep duration in the chronic phase of 
moderate to severe traumatic brain injury  
• TBI adults complain of significant sleepiness, fatigue and poorer sleep than controls. 
• No trace of sleep disturbances were found with actigraphy in TBI group. 
• TBI adults spent more time in bed to increase time asleep and decrease drowsiness. 
• Daytime complaints were associated with more severe injuries and comorbidities. 
• Medicated TBI adults present more evidences of sleep-wake change.   
